Nama Insights

Ionis Pharmaceuticals (IONS)

Healthcare · Biotechnology · NASDAQ

Ionis Pharmaceuticals (IONS) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $4.53B and a free-cash-flow yield of -7.5%. Over the most recent reported fiscal year, revenue grew 33.8%. Nama's AI scorecard rates it Sell, 3.6 out of 10. On 12-month momentum it ranks in the trailing band of its market.
AI scorecard
Sell · 3.6/10
Negative, at the mild end of Sell. As of Nov 20, 2026.
Momentum
Trailing · -39.5% over 12 months ex. last
Bottom 20% of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-69.4%
How far the last close sits under the highest price of the past five years.
Market cap$4.53B
Trailing P/E—
Price / book11.5
Price / sales4.7
FCF yield-7.5%
Dividend yield—
Gross margin98.2%
Operating margin-58.8%
Net margin-56.9%
Revenue growth (YoY)+33.8%
Revenue growth (3-yr annual)+17.1%
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta0.4
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

IONS earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate -$0.93). Beat the EPS estimate in 4 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 9, 2026 -$0.40 -$0.93 +57.0% $242.72M
Q2 2026 Jul 29, 2026 -$0.42 -$0.88 +52.3% $267.95M
Q1 2026 Apr 29, 2026 -$0.30 -$0.77 +61.0% $246.09M
Q4 2025 Feb 25, 2026 -$1.15 -$1.22 +5.7% $203.33M

IONS analyst price target

Median target $68.00 from 23 analysts, ranging $41.00 – $105.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live IONS data on Nama Insights →

Recent Congressional trades

Ionis Pharmaceuticals trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member Chamber Trade Amount Disclosed
Sheldon Whitehouse Senate Sell $1,001 - $15,000 —

IONS FAQ

Is IONS a buy?
Nama's AI scorecard currently rates Ionis Pharmaceuticals Sell (3.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does IONS report earnings?
Ionis Pharmaceuticals's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$0.93.
What is the IONS price target?
The median analyst price target from 23 analysts is $68.00, with a range of $41.00 – $105.00.
Is IONS Shariah compliant?
Nama's AAOIFI-style screen reads Ionis Pharmaceuticals as Can't Tell. A figure the screen needs is missing, so it can't tell.